ARCHIVES

In Brief: What’s In A Name? DRCCA Doesn’t Do It; O’Conor Says ICRDB Program Should Consider New Challenges

This article is from The Cancer Letter archive.

Vol. 06 No. 39 | October 3, 1980

Download PDF Visit The Full Archive

Related Articles

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

June 16, 1999

Program Project Payline Is 125; Budget Cuts Will Allow NCI To Fund 49 Competing P01s

February 28, 1992

Vanderbilt Recruits Sosman To Lead Tumor Immunology.

January 18, 2002

First Formal CREG Guidelines, Rules Publishes

June 6, 1975

In Brief: Simone, LoBuglio Lead AACI; AMA Honors B.J. Kennedy; FDA Meet Patient Advocates

July 31, 1992

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011